Exelixis | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 223.92M 13.87M 2025-03
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
Amgen USD 5.54B 430M 2025-03
AstraZeneca USD 11.35B 819M 2025-03
Bayer EUR 8.11B 2.11B 2025-03
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Cytokinetics -160545000 81.19M 2024-09
Eisai JPY 147.63B 22.57B 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Exelixis USD 536.28M 10.51M 2025-04
Genmab DKK 673M 5.43B 2025-03
Glaxosmithkline GBP 5.6B 94M 2024-12
Incyte USD 985.09M 111.22M 2025-03
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
MacroGenics USD 13.86M 94.98M 2024-12
Merck USD 12.77B 849M 2025-03
Moderna USD 17M 403M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Pfizer USD 11.12B 987M 2025-03
Sanofi EUR 5.36B 4.71B 2024-12
Takeda JPY 671.32B 55.93B 2025-03
Ultragenyx Pharmaceutical USD 110.63M 37.35M 2025-03
Xencor -45143000 40.69M 2024-09



Exelixis Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.